Next Article in Journal
Lipid Metabolic Reprogramming in Hepatocellular Carcinoma
Previous Article in Journal
Pharmacokinetics of Sublingually Delivered Fentanyl in Head and Neck Cancer Patients Treated with Curatively Aimed Chemo or Bioradiotherapy
Previous Article in Special Issue
In Vivo Evaluation of a New Recombinant Hyaluronidase to Improve Gene Electro-Transfer Protocols for DNA-Based Drug Delivery against Cancer
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessArticle
Cancers 2018, 10(11), 446; https://doi.org/10.3390/cancers10110446

Tumor-Targeted Immunotherapy by Using Primary Adipose-Derived Stem Cells and an Antigen-Specific Protein Vaccine

1
Graduate Institute of Biomedical Materials and Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 110, Taiwan
2
Stem Cell Research Center, College of Oral Medicine, Taipei Medical University, Taipei 110, Taiwan
3
School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei 110, Taiwan
4
Department of Dentistry, Taipei Medical University Hospital, Taipei 110, Taiwan
5
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 110i, Taiwan
6
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University School of Medicine, Taipei 110, Taiwan
7
Ceramics and Biomaterials Research Group, Advanced Institute of Materials Science, Ton Duc Thang University, Ho Chi Minh City 700000, Vietnam
8
Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City 700000, Vietnam
9
Department of Neurosurgery, Taipei Medical University Hospital, Taipei 110, Taiwan
10
School of Medicine, Taipei Medical University, Taipei 110, Taiwan
11
Department of Periodontics, College of Dental Medicine, Columbia University, New York 10032, USA
12
School of Dental Technology, College of Oral Medicine, Taipei Medical University, Taipei 110, Taiwan
13
Graduate Institute of Basic Medicine, Fu Jen Catholic University, New Taipei City 110, Taiwan
*
Authors to whom correspondence should be addressed.
Received: 14 September 2018 / Revised: 9 November 2018 / Accepted: 12 November 2018 / Published: 15 November 2018
(This article belongs to the Special Issue Cancer Vaccines: Research and Applications)
Full-Text   |   PDF [6087 KB, uploaded 15 November 2018]   |  

Abstract

Cancer is a leading cause of mortality and a major public health problem worldwide. For biological therapy against cancer, we previously developed a unique immunotherapeutic platform by combining mesenchymal stem cells with an antigen-specific protein vaccine. However, this system possesses a few limitations, such as improperly immortalized mesenchymal stem cells (MSCs) along with transfected oncogenic antigens in them. To overcome the limitations of this platform for future clinical application, we freshly prepared primary adipose-derived stem cells (ADSCs) and modified the E7’ antigen (E7’) as a non-oncogenic protein. Either subcutaneously co-inoculated with cancer cells or systemically administered after tumor growth, ADSC labeled with enhanced green fluorescent protein (eGFP) and combined with modified E7’ (ADSC-E7’-eGFP) cells showed significant antitumor activity when combined with the protein vaccine in both colon and lung cancer in mice. Specifically, this combined therapy inhibited tumor through inducing cell apoptosis. The significantly reduced endothelial cell markers, CD31 and vascular endothelial growth factor (VEGF), indicated strongly inhibited tumor angiogenesis. The activated immune system was demonstrated through the response of CD4+ T and natural killer (NK) cells, and a notable antitumor activity might be contributed by CD8+ T cells. Conclusively, these evidences imply that this promising immunotherapeutic platform might be a potential candidate for the future clinical application against cancer. View Full-Text
Keywords: adipose-derived stem cells; protein vaccine; T cell responses; tumor microenvironment; antigen processing adipose-derived stem cells; protein vaccine; T cell responses; tumor microenvironment; antigen processing
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Lu, J.-H.; Peng, B.-Y.; Chang, C.-C.; Dubey, N.K.; Lo, W.-C.; Cheng, H.-C.; Wang, J.R.; Wei, H.-J.; Deng, W.-P. Tumor-Targeted Immunotherapy by Using Primary Adipose-Derived Stem Cells and an Antigen-Specific Protein Vaccine. Cancers 2018, 10, 446.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top